AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

GlaxoSmithKline aims to turbo-charge the company’s drug discovery engine with a big bet on genetics as its CEO played down the idea of hiving off consumer healthcare.

Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Shares of Teva Pharmaceutical were up following news reports that billionaire investor Warren Buffett took a stake in the company.